- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Urethral Cancer Associated With Invasive Bladder Cancer in Korea, Democratic People's Republic of
Total 101 results
-
Samsung Medical CenterActive, not recruitingNon-Small Cell Lung Cancer With EGFR T790M Mutation | With Brain and/or Leptomeningeal Metastasis | Failed Tyrosine Kinase InhibitorsKorea, Republic of
-
Merck Sharp & Dohme LLCRecruitingHigh-risk Non-muscle Invasive Bladder CancerCanada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Colombia, ... and more
-
Yonsei UniversityRecruitingTriple Negative Breast Cancer | Metastatic Breast Cancer With HER2 PositiveKorea, Republic of
-
Gachon University Gil Medical CenterCompletedColorectal Cancer With Liver MetastasisKorea, Republic of
-
Astellas Pharma Global Development, Inc.Seagen Inc.Active, not recruitingBladder Cancer | Urothelial Cancer | Ureteral CancerUnited States, Japan, Korea, Republic of, Taiwan, Argentina, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Portugal, Russian Federation, Spain, Switzerland, United Kingdom
-
Yonsei UniversityWithdrawnGastric Cancer With Metabolic Syndrome or Metabolic DiseaseKorea, Republic of
-
PfizerActive, not recruitingNon-muscle Invasive Bladder CancerChina, United States, Spain, Belgium, Korea, Republic of, Australia, United Kingdom, Japan, France, Germany, Canada, Russian Federation, Poland, Italy
-
Bristol-Myers SquibbPierre Fabre MedicamentCompletedKidney Neoplasms | Transitional Cell Carcinoma | Bladder Cancer | Bladder Neoplasms | Ureter Neoplasms | Neoplasm, BladderUnited States, Spain, Italy, Canada, Indonesia, Singapore, Australia, Austria, France, Greece, Korea, Republic of, Philippines, Sweden, Switzerland, Thailand
-
Soonchunhyang University HospitalMinistry of Health & Welfare, KoreaActive, not recruitingDuctal Carcinoma in Situ | Invasive CancerKorea, Republic of
-
Nippon Kayaku Co., Ltd.Handok Inc.TerminatedBladder CancerJapan, Korea, Republic of
-
BeiGeneCompletedLocally Advanced or Metastatic Urothelial Bladder CancerKorea, Republic of, China
-
Samsung Medical CenterTerminatedPhase I: To Determine the Maximum Tolerated Dose (MTD) | Phase II: To Assess the Pathologic CR Rate and Feasibility Following Neoadjuvant Chemoradiation Therapy With S1/OxaliplatinKorea, Republic of
-
Seoul National University HospitalCompletedInvasive Breast Cancer | Carcinoma, Ductal, Breast | IMAGEKorea, Republic of
-
Janssen Research & Development, LLCRecruitingBladder CancerUnited States, Belgium, Korea, Republic of, Italy, Taiwan, China, United Kingdom, Germany, France, Argentina, Brazil, Poland, Spain, Japan, Netherlands, India, Canada, Czechia, Mexico, Australia, Portugal
-
Yonsei UniversityTakedaRecruitingPlatinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP InhibitorKorea, Republic of
-
AstraZenecaCompletedPancreatic Ductal Adenocarcinoma | Triple-negative Breast Cancer | Urothelial Bladder CancerUnited States, Belgium, Korea, Republic of, Poland, Netherlands
-
Samsung Medical CenterUnknownCorrection of Cancer-related Coagulopathy With Novel Oral Anticoagulant (Edoxaban)Korea, Republic of
-
AstraZenecaRecruitingMuscle Invasive Bladder CancerNetherlands, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Poland, Spain, Turkey, Vietnam, Argentina, Japan, France, Brazil, Taiwan, United States, Israel, Austria, Chile, Colombia, Greece, Hong Kong, Mexico, Portugal, Russian... and more
-
AstraZenecaActive, not recruitingMuscle Invasive Bladder CancerUnited States, Belgium, France, Germany, Italy, Spain, United Kingdom, Canada, Poland, Taiwan, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Japan, Philippines, Israel, Chile, Australia, Netherlands, Russian Federation
-
Bristol-Myers SquibbOno Pharmaceutical Co. LtdActive, not recruitingUrinary Bladder Neoplasms | Muscle-Invasive Bladder CancerRussian Federation, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Finland, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Portugal, Roman... and more
-
Janssen Research & Development, LLCRecruitingNon-Muscle Invasive Bladder NeoplasmsKorea, Republic of, United States, Argentina, Belgium, Brazil, China, Poland, United Kingdom, Italy, Japan, Germany, Romania
-
Hoffmann-La RocheRecruitingMuscle-invasive Bladder CancerBelgium, Korea, Republic of, Japan, Brazil, China, United States, Singapore, France, United Kingdom, Canada, Greece, Italy, Spain, Turkey, Russian Federation, Ukraine, Israel, Czechia, Colombia, Hong Kong, Argentina, Germany, Ireland, Polan... and more
-
Janssen Research & Development, LLCRecruitingUrinary Bladder NeoplasmsUnited States, Belgium, Korea, Republic of, Germany, Italy, France, Spain, Canada, United Kingdom, Greece, Japan, Australia, Netherlands, Portugal, Russian Federation, Ukraine
-
Merck Sharp & Dohme LLCSeagen Inc.; Astellas Pharma Global Development, Inc.Active, not recruitingUrinary Bladder Cancer, Muscle-invasiveCanada, United States, Australia, Belgium, France, Hungary, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Thailand, Ukraine, Argentina, Colombia, Denmark, Germany, Ireland, Israel, Japan, Malaysia, Philippines, Sing... and more
-
Janssen Research & Development, LLCActive, not recruitingUrinary Bladder NeoplasmsUnited States, Japan, China, Korea, Republic of, France, Belgium, Czechia, Taiwan, Italy, Poland, United Kingdom, Spain, Germany, Australia, Brazil, Argentina, India
-
GI Innovation, Inc.Merck Sharp & Dohme LLCRecruitingMelanoma | Sarcoma | Renal Cell Carcinoma | Cervical Cancer | Urinary Bladder Cancer | Vulvar Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Vaginal Cancer | Microsatellite Stable...Korea, Republic of, United States
-
Novartis PharmaceuticalsCompletedAdvanced Triple Negative Breast Cancer (TNBC) With High TAMsFrance, Italy, Austria, Taiwan, United States, Spain, Australia, Korea, Republic of, Belgium, Germany, Hong Kong, Turkey
-
Five Prime Therapeutics, Inc.CompletedGastric Cancer | Advanced Solid Tumors | Transitional Cell Carcinoma of the BladderKorea, Republic of, United States, Taiwan
-
Hoffmann-La RocheCompletedBladder CancerUnited States, France, Belgium, Korea, Republic of, United Kingdom, Czechia, Austria, Canada, Denmark, Greece, Italy, Netherlands, Portugal, Slovenia, Spain, Sweden, Turkey, Poland, Hungary, Switzerland, Japan, Taiwan, Australia, Norway, Germa... and more
-
German Breast GroupPfizer; AGO Study Group; Breast International Group; NSABP Foundation IncCompletedBreast Cancer | Hormonreceptor Positive | Her2-normal | Postneoadjuvant Treatment With CDK 4/6 Inhibitor | CPS-EG ScoreUnited States, Australia, Austria, Canada, France, Germany, Ireland, Japan, Korea, Republic of, Spain, United Kingdom
-
Daiichi Sankyo, Inc.AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...Active, not recruitingHER2-Positive Primary Breast Cancer | Residual Invasive Breast CancerUnited States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
-
Hoffmann-La RocheGilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and AstellasRecruitingBladder Cancer | Urothelial CarcinomaUnited States, Spain, Korea, Republic of, United Kingdom, Taiwan, France, Greece
-
Elevation OncologyActive, not recruitingSarcoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Cholangiocarcinoma | Bile Duct Cancer | Bladder Cancer | Metastatic Solid Tumor | Gallbladder Cancer | Uterine Cancer | Locally Advanced Solid TumorUnited States, Korea, Republic of, Australia, Canada
-
Kura Oncology, Inc.CompletedThyroid Cancer | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | HRAS Mutant Tumor | Other Squamous Cell Carcinoma (SCC) With HRAS Mutant TumorSpain, United States, Korea, Republic of, France, Belgium, Germany, Greece, Italy, Netherlands, United Kingdom
-
Medicenna Therapeutics, Inc.Merck Sharp & Dohme LLCRecruitingClear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditionsUnited States, Australia, Korea, Republic of, Canada
-
PfizerCompletedNon-small Cell Lung Cancer With EGFR-Activating MutationsItaly, Poland, China, Hong Kong, Spain, Korea, Republic of, Japan
-
Taiho Oncology, Inc.CompletedBreast Cancer | Gastric Cancer | Cholangiocarcinoma | Urothelial Cancer | Primary CNS Tumors | Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR TumorsFrance, United States, Korea, Republic of, United Kingdom, Japan, Hong Kong, Australia, Taiwan, Italy, Canada, Germany, Netherlands, Spain
-
Day One Biopharmaceuticals, Inc.RecruitingMelanoma | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Thyroid Cancer, Papillary | Pilocytic Astrocytoma | Bladder Urothelial Carcinoma | Non-Small Cell Adenocarcinoma | MEK Mutation | RAS Mutation | Pancreatic Acinar Carcinoma | RAF Mutation | CRAF Gene Amplification | RAF1 Gene Amplification and other conditionsUnited States, Canada, Korea, Republic of, Spain, Australia, Belgium, France
-
Merck Sharp & Dohme LLCActive, not recruitingBladder CancerCanada, United States, Australia, Belgium, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Sweden, Thailand, Turkey, Ukraine, United Kingdom
-
Bristol-Myers SquibbCompletedTransitional Cell Carcinoma | Bladder Cancer | MetastasisUnited States, Korea, Republic of, United Kingdom, Spain, Australia, France, Thailand, Denmark, Poland, Belgium, Italy, Philippines, Canada, Russian Federation, Greece, Indonesia
-
AstraZenecaRecruitingCervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Biliary Cancer | Additional Indications Below for Module 4 and 5 | Small Cell Lung Cancer Only in Module 5Canada, Spain, China, Korea, Republic of, Italy, Poland, United States, Australia, United Kingdom, Japan, Hungary, Russian Federation, Czechia
-
Merck Sharp & Dohme LLCAstellas Pharma Inc; Seagen Inc.Active, not recruitingBladder CancerHungary, United States, China, Argentina, Australia, Bulgaria, Canada, Colombia, Croatia, Czechia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, Philippines, Poland, Portugal, Romania, Russian Federation, Singapo... and more
-
AstraZenecaDaiichi Sankyo Co., Ltd.RecruitingPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerCanada, Korea, Republic of, Taiwan, United States, Italy, United Kingdom, Thailand, Russian Federation, India, Belgium, Australia, Poland, Spain, Japan, Brazil, Czechia, Netherlands
-
Galena Biopharma, Inc.CompletedBreast Cancer With Low to Intermediate HER2 ExpressionUnited States, United Kingdom, France, Israel, Germany, Canada, Russian Federation, Romania, Bulgaria, Czech Republic, Hungary, Poland, Ukraine
-
Daiichi SankyoDaiichi Sankyo Co., Ltd.Active, not recruitingNon-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorUnited States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
-
Astellas Pharma IncCompletedNon-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based ChemotherapyUnited Kingdom, United States, Brazil, Canada, Germany, Korea, Republic of, Poland, Romania, Russian Federation
-
Boehringer IngelheimRecruitingLung Neoplasms | Pancreatic Neoplasms | Bladder Cancer | Solid Tumors | Biliary Tract CancerUnited States, Korea, Republic of, Spain, Australia, Japan, Germany, Taiwan, Singapore, Thailand, France, Belgium, Austria, Switzerland, United Kingdom, South Africa
-
Ascendis Pharma Oncology Division A/SRecruitingAdvanced Solid Tumor | Metastatic Solid Tumor | Locally Advanced Solid Tumor | Neoadjuvant Melanoma | Head and Neck Squamous Cell Carcinoma HNSCC | HPV-associated Cancers | Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)United States, Australia, Spain, Netherlands, Korea, Republic of, Taiwan
-
Taiho Oncology, Inc.RecruitingAdvanced or Metastatic NSCLS With Exon 20 Insertion MutationUnited States, Spain, Canada, Italy, Israel, Japan, United Kingdom, Korea, Republic of, Germany, France, Turkey, Belgium, Netherlands, Philippines, Poland, Singapore
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyActive, not recruitingAdvanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IVSpain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland